|
|
| Line 1: |
Line 1: |
| [[Image:Haemophilus i..jpg|thumb|220px|Haemophilus influenzae on a blood agar plate]] | | [[Image:Haemophilus i..jpg|thumb|220px|Haemophilus influenzae on a blood agar plate]] |
| {{SI}} | | {{Hemophilus influenza serotype B infection}} |
| {{CMG}} | | {{CMG}} |
|
| |
|
| Line 14: |
Line 14: |
| '''Etiologic agent''' | | '''Etiologic agent''' |
|
| |
|
| Haemophilus influenzae serotype b.
| | |
|
| |
|
| '''Transmission''' | | '''Transmission''' |
|
| |
|
| Direct contact with respiratory droplets from nasopharyngeal carrier or case patient.
| | |
|
| |
|
| == Natural History == | | == Natural History == |
|
| |
| Haemophilus influenzae, formerly called Pfeiffer's bacillus or Bacillus influenzae, is a non-motile Gram-negative coccobacillus first described in 1892 by Richard Pfeiffer during an influenza pandemic. It is generally aerobic, but can grow as a facultative anaerobe. H. influenzae was mistakenly considered to be the cause of the common flu until 1933, when the viral etiology of the flu became apparent. Still, H. influenzae is responsible for a wide range of clinical diseases.
| |
|
| |
| Because of its small genome, H. influenzae became the first free-living organism with its entire genome sequenced. Its genome consists of 1,830,140 base pairs of DNA and contains 1740 genes. The method used was Whole genome shotgun. The sequencing project, completed and published in Science in 1995, was conducted at The Institute for Genomic Research.
| |
|
| |
|
| == Diagnosis == | | == Diagnosis == |
|
| |
|
| === History and Symptoms === | | === History and Symptoms === |
|
| |
| Before the availability of the Haemophilus influenzae serotype b (Hib) conjugate vaccine in the United States and other industrialized countries, more than one-half of Hib cases presented as [[meningitis]] with [[fever]], [[headache]], and stiff neck. The remainder presented as [[cellulitis]], [[arthritis]], or [[sepsis]]. In developing countries, Hib is still a leading cause of bacterial pneumonia deaths in children.
| |
|
| |
|
| == Risk Stratification and Prognosis== | | == Risk Stratification and Prognosis== |
|
| |
| 3%-6% of cases are fatal; up to 20% of surviving patients have permanent hearing loss or other long-term sequelae.
| |
|
| |
|
| == Treatment == | | == Treatment == |
|
| |
|
| Specific parenteral antibiotic treatment is necessary for invasive Hib disease, and immediate airway stabilization is necessary for epiglottitis. Antibiotic prophylaxis with rifampin is indicated for all household contacts in the following circumstances: households with a contact aged 4 years or younger who is unimmunized or underimmunized, households with a child aged younger than 12 months who has not received the primary series, and households with an immunocompromised child. Chemoprophylaxis is not recommended for pregnant women or for child care contacts with a single index case, but the children’s vaccination history should be reviewed to ensure completion of the recommended schedule of Hib conjugate vaccine. A 4-day course of rifampin eradicates Hib carriage from the pharynx in approximately 95% of carriers.
| | === Primary Prevention === |
|
| |
|
| === Primary Prevention ===
| |
|
| |
|
| [[Haemophilus Influenzae Type b (Hib) Vaccine]]
| |
|
| |
|
| === Future or Investigational Therapies === | | === Future or Investigational Therapies === |
| Line 48: |
Line 38: |
| '''Challenges''' | | '''Challenges''' |
|
| |
|
| Elimination of persistent Hib disease in the United States. Currently available conjugate vaccines differ in immuno-genicity in very young children and possibly in duration of antibody persistence, raising questions about long-term efficacy (>5 years), optimal use, and schedules. Monitoring the possible emergence of disease due to other serotypes. Problems with serotyping of H. influenzae in state health departments. Development of rapid molecular assays for detection and molecular subtyping of all Hi strains. The cost of Hib conjugate vaccines has limited their use in developing countries even though Hib is a major cause of morbidity and mortality.
| | |
|
| |
|
| '''Opportunities''' | | '''Opportunities''' |
|
| |
|
| Evaluating the characteristics of Hib vaccines associated with prevention of carriage and invasive disease will facilitate application of this technology to development of conjugate vaccines for other organisms with polysaccharide capsules (such as the meningococcus, pneumococcus, and group B streptococcus). Further evaluation of herd immunity effects may lead to insight into vaccination strategies that optimize protection against invasive disease and transmission of Hib organisms.
| |
|
| |
|
| ==References== | | |
| | ==External Links== |
|
| |
|
| #http://www.cdc.gov/ncidod/dbmd/diseaseinfo/histoplasmosis_g.htm | | #http://www.cdc.gov/ncidod/dbmd/diseaseinfo/histoplasmosis_g.htm |
| #http://wwwn.cdc.gov/travel/yellowBookCh4-FluMeningitis.aspx | | #http://wwwn.cdc.gov/travel/yellowBookCh4-FluMeningitis.aspx |
|
| |
| == Acknowledgements ==
| |
|
| |
| The content on this page was first contributed by: C. Michael Gibson, M.S., M.D.
| |
|
| |
|
| |
|
| {{WH}} | | {{WH}} |
